TrialBlood cancer journal2026

Firstline treatment with ruxolitinib versus best available therapy in patients with polycythemia vera: results from the randomized RuxoBEAT trial.

Steffen Koschmieder et al.PubMed ↗Publisher ↗

No numbers read from the abstract.